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Abstract
Background: Relapses occur in about 20% of children with acute lymphoblastic leukemia (ALL). Approximately one-third of
these children can be cured. Their risk for late effects is high because of intensified treatment, but their health-related
quality of life (HRQOL) was largely unmeasured. Our aim was to compare HRQOL of ALL survivors with the general
population, and of relapsed with non-relapsed ALL survivors.
Methodology/Principal Findings: As part of the Swiss Childhood Cancer Survivor Study (SCCSS) we sent a questionnaire to
all ALL survivors in Switzerland who had been diagnosed between 1976–2003 at age ,16 years, survived $5 years, and
were currently aged $16 years. HRQOL was assessed with the Short Form-36 (SF-36), which measures four aspects of
physical health and four aspects of mental health. A score of 50 corresponded to the mean of a healthy reference
population. We analyzed data from 457 ALL survivors (response: 79%). Sixty-one survivors had suffered a relapse. Compared
to the general population, ALL survivors reported similar or higher HRQOL scores on all scales. Survivors with a relapse
scored lower in general health perceptions (51.6) compared to those without (55.8;p = 0.005), but after adjusting for self-
reported late effects, this difference disappeared.
Conclusion/Significance: Compared to population norms, ALL survivors reported good HRQOL, even after a relapse.
However, relapsed ALL survivors reported poorer general health than non-relapsed. Therefore, we encourage specialists to
screen for poor general health in survivors after a relapse and, when appropriate, specifically seek and treat underlying late
effects. This will help to improve patients’ HRQOL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
cancer in children younger than 15 years of age, accounting for
about 28% of malignancies in the pediatric population [1,2].
Therapy has dramatically improved over the last decades and
overall survival for children with ALL is now 85% [3,4].
Nevertheless, about 15–20% of children with ALL suffer from
relapse [5]. Current salvage protocols result in cures for 37% of
these patients, who undergo intensified chemotherapy, often
including central nervous system irradiation and/or stem cell
transplantation [6]. The disease and its treatment put ALL
survivors are at risk for somatic and neuropsychological late effects
and second malignancies [7–11]. This is particularly true of
survivors of relapsed ALL, who more frequently develop more
severe chronic medical conditions, affecting more organ systems,
than non-relapsed ALL survivors. Late effects are observed in
cardiac, endocrine, neurologic, renal, and visual systems [12,13].
We know a good deal about late effects, but less is known about
health-related quality of life (HRQOL) of relapsed and non-
relapsed ALL survivors [14–17]. HRQOL assesses subjectively
perceived functioning [18,19] and is a multidimensional construct
of physical, psychological and social well being and the capacity to
perform the activities of daily life. Three previous studies have
compared HRQOL of ALL survivors with population norms and
reported similar or slightly lower HRQOL in survivors [20–22],
but they did not distinguish between patients who had relapsed
and those who had not. Studies of a cohort of childhood cancer
survivors with different diagnoses reported that relapse had no
effect on HRQOL [14,15], but others studies found more than
one treatment series (as a proxy for relapse) to be independently
associated with poorer HRQOL [16]. A small hospital-based study
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in Finland found better HRQOL in relapsed ALL survivors
compared to ALL survivors without relapse and to healthy
controls [17].
Our goal was to better understand the role that relapse plays in
the HRQOL of patients who have survived the complex course of
ALL and its treatment. Therefore, we compared HRQOL of ALL
survivors with the general population (1) and of relapsed and non-
relapsed ALL survivors, accounting for late effects (2).
Methods
Ethics Statement
Since 2004, all patients and their families give informed consent
at the time of cancer diagnosis for their data to be included in the
Swiss Childhood Cancer Registry (SCCR) and used for research.
Patients who had been diagnosed in the early years of the registry
received the information retrospectively and could object to their
inclusion in the registry (right of veto). This procedure was decided
by the Swiss Federal Commission of Experts for Professional
Secrecy in Medical Research when granting the general cancer
registry permission to the SCCR, and was endorsed by the ethics
committee of the canton of Bern. Similarly, the questionnaire
survey of the Swiss Childhood Cancer Survivor Study was
approved by the ethics committee of the canton of Bern. When
returning the questionnaire, cancer survivors consented that their
data are used for research. All information regarding individuals
was made anonymous to investigators prior to analysis.
Sample and Procedure
The Swiss Childhood Cancer Survivor Study (SCCSS) is a
population-based long-term follow-up study of all childhood
cancer patients registered in the Swiss Childhood Cancer Registry
(SCCR), diagnosed 1976–2003, who survived for at least 5 years
[7,23]. The SCCR includes all children and adolescents in
Switzerland diagnosed with leukemia, lymphoma, central nervous
system tumors, malignant solid tumors or Langerhans cell
histiocytosis before age 16 years [2,24].
Eligible participants were traced with an extensive address
search procedure. Between 2007 and 2010, survivors with
identified addresses received an information letter from their
former pediatric oncology clinic, followed in two weeks by a
questionnaire that included a pre-paid return envelope. Four
weeks later, non-responders received a reminder letter, and a
phone call six weeks later. Letters and questionnaires were written
in the three national languages: German, French and Italian. For
the current analyses we included only ALL survivors at least 16
years old at the time of the study, who had had no relapse and no
second malignancies in the five years before survey. For the
current analyses we included only ALL survivors at least 16 years
old at the time of the study, who had had no relapse and no second
malignancies in the five years before survey. This was done
because we wanted to assess quality of life in state of relative health
not during treatment of a relapse or second tumor.
Measurements
a) Health-Related Quality of Life. The SCCSS used an
extensive questionnaire similar to that used in US and British
childhood cancer survivors studies [25,26]. It included the Short
Form-36 (SF-36) to measure HRQOL [27]. This instrument SF-
36 is psychometrically tested and available in several languages
[19,27,28]. The SF-36 has been successfully used in samples of
long-term childhood cancer survivors [20,22], and is valid and
reliable [29]. It consists of 36 questions that can be aggregated into
eight scales: physical functioning, role limitations due to physical
health, bodily pain, general health perceptions, vitality, social
functioning, role limitations due to emotional problems, and
mental health (Table S1). We standardized the survivors’ scores
as T-scores according to separate German, French and Italian
population norms [30–32], using a general population mean of 50
and standard deviation of 10. A public-use file from the German
Federal Health Survey (N= 6964) allowed us to select a subgroup
similar in age and gender distribution to the survivors [33]. Higher
scores indicate better HRQOL.
b) Clinical and Socio-Demographic
Information. Information on baseline demographics and pro-
spectively collected medical information on survivor diagnosis and
treatment was extracted from the Swiss ChildhoodCancer Registry:
current age; gender; age at diagnosis; time since diagnosis; chemo-
and radiotherapy (chemotherapy: without radiotherapy, may have
surgery/radiotherapy: with or without chemotherapy or surgery);
bone marrow transplantation; duration of therapy; and relapse
status. Therapy variables included treatment both for initial and
relapsed ALL. This information was extracted from the SCCSS
questionnaire: having a partner (yes/no); education; and self-
reported late effects. Education was divided into four categories
according to the Swiss Census: compulsory schooling; vocational
training; upper secondary education; and, university education [34].
Survivors were asked whether they experienced any late effects of
their cancer or treatment (yes/no) to assess late effects. Late effects
were defined as adverse long-term outcomes of cancer or treatment,
including somatic and psychological problems, as described by the
survivors in open format. Relapse was not considered a late effect.
Statistical Analyses
a) Quality of HRQOL Data. We determined the quality of
HRQOL data by calculating missing values per item, item-scale
internal consistency, and Cronbach’s alpha.
b) Comparison with Norm Population and within
Survivor Population. We calculated the ALL survivors’ (all,
relapsed only, non-relapsed only) mean t-scores for each scale to
find out if they were within one standard deviation of the
population norms (Aim 1). HRQOL within one standard
deviation of the general population was considered ‘‘normal’’ [22].
We also compared HRQOL of relapsed with non-relapsed ALL
survivors (Aim 2), performing univariable and multivariable linear
regressions for each SF-36 scale (dependent variables). Relapse
status was the independent variable in univariable analysis. We
added more variables in two steps in multivariable analysis:
A. Step 1, baseline model, adjusting for possible confounders
(variables: gender, current age, time since diagnosis);
B. Step 2, extended models, adjusting for additional variables to
investigate associations between relapse and HRQOL:
i. Social model (having a partner, education)
ii. Therapy model (chemo2/radiotherapy, bone marrow
transplantation, duration of therapy)
iii. Late effects model (self-reported late effects)
iv. Full model (adjusting for all variables)
We performed in-depth analysis of SF-36 scales associated with
relapse status checking the answers that aggregated into the
respective scales.
c) Sensitivity Analyses. In sensitivity analyses, we used the
French and Italian population norms instead of the German.
Analyses were carried out using the software package STATA
version 12 (Stata Corporation, Austin, TX, USA).
Quality of Life after Relapsed Childhood Leukemia
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Results
We successfully traced addresses for 621 of 658 eligible ALL
survivors (Figure 1). Of those, 490 (79% of contacted) returned
the questionnaire. We excluded from the analysis survivors who
answered an abridged questionnaire without an SF-36 (n = 33),
which limited our sample to 457 survivors (74% of contacted).
Characteristics of the Study Population
Participants (n = 457) were more often female (50% vs. 35%,
p= 0.001), and more often treated with a bone marrow
transplantation (11% vs. 4%, p= 0.016) than those who did not
reply or completed only an abridged questionnaire (n = 164)
(Table 1). There was no difference in current age, age at
diagnosis, time since diagnosis, chemo2/radiotherapy, duration of
therapy or relapse status.
Compared to survivors of non-relapsed ALL (n= 396), survivors
of relapsed ALL (n = 61) were older, diagnosed earlier, more likely
to report late effects, and more likely to have received
radiotherapy, bone marrow transplant or treatment lasting 3
years or longer. There was no difference in gender, relationship
status, education, or age at diagnosis.
Quality of HRQOL Data
Data on HRQOL was nearly complete, missing values per item
ranging from 1–2%. The correlation between each item with its
hypothesized scale exceeded the suggested standard of 0.40 for
satisfactory item-consistency (0.44–0.82). Cronbach’s alpha was
high for all scales (0.78–0.90) suggesting good reliability.
Comparison with Norm Population
Compared with the German population norm, survivors’ scores
on all HRQOL scales were similar or higher (Table 2). Mean
scores for all SF-36 scales were within one standard deviation of
the norm no matter the relapse status: Relapsed ALL survivors
scored lowest in the scale ‘‘role emotional’’ (47.4) and highest in
the scale ‘‘bodily pain’’ (57.1); non-Relapsed ALL survivors scored
lowest score in ‘‘role emotional’’ (49.1) and highest in ‘‘vitality’’
(57.4).
Comparison within Survivor Population
In a comparison of relapsed and non-relapsed ALL survivor
HRQOL, those who relapsed tended to be low in some SF-36
scales, but on only one scale was relapse significantly associated in
univariable analysis. Survivors of relapsed ALL had a lower
‘‘general health’’ score than survivors of non-relapsed ALL (51.6
vs. 55.8, p= 0.005).
In multivariable analysis, the difference in general health
between survivors with and without relapse remained statistically
significant in baseline, social and therapy models (51.1 vs. 55.9,
p = 0.003; 51.2 vs. 55.8, p = 0.004; 56.0 vs. 50.8, p= 0.008)
(Table S2). However, when we adjusted for self-reported late
effects, the difference in SF-36 scales disappeared (‘‘general
health’’ in late effects model: 53.9 vs. 55.4, p = 0.359; ‘‘general
health’’ in full model: 53.0 vs. 55.8, p= 0.135; Figure 2).
We looked at the distribution of the answers aggregated into
‘‘general health’’ in order to better understand the difference.
Fewer survivors of relapsed ALL chose the statements, ‘‘I am as
healthy as anybody I know,’’ and, ‘‘My health is excellent,’’ than
survivors of non-relapsed ALL (38% vs. 58%, p= 0.006; and 39%
vs. 55%, p= 0.004 respectively) (Table 3).
Sensitivity Analysis
Repeated analyses with French and Italian norm population
HRQOL produced similar results, both in univariable and in
multivariable regressions (Tables S3 and S4).
Figure 1. Participant status of acute lymphoblastic leukemia survivors in the Swiss Childhood Cancer Survivor Study. As of May 19,
2011. *of those traced and sent questionnaire. ALL: acute lymphoblastic leukemia; SF-36: Short Form-36.
doi:10.1371/journal.pone.0038015.g001
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Discussion
We found that ALL survivors, on average, reported HRQOL
similar to the norm population, even after a relapse. Survivors of
relapsed ALL perceived their general health to be lower than did
non-relapsed ALL survivors. This difference became insignificant
when we adjusted for late effects, indicating that late effects are a
major underlying reason for the lower HRQOL in relapsed
survivors.
Strengths and Limitations of the Present Study
A major strength of our study is the focus on relapse in ALL
survivors. Most previous studies mixed all relapses across
diagnostic groups. This was a problem because relapse is defined
differently and leads to different treatment modifications. Large
sample size, high response rate and the population-based nature of
our study make it stronger than most other studies that
investigated the role of relapse on HRQOL in childhood cancer
survivors (Table 4).
Our study also has limitations. Due to limited statistical power
we could not look at different subgroups of relapses (late or early,
isolated bone marrow or extramedullary relapses, combined
relapses), nor could we distinguish between different subgroups
of late effects. We did not consider the exact drugs and cumulative
doses used in treatment, nor the sites of radiation. Finally, no SF-
36 norm data is available for Switzerland.
Comparison with Other Studies
Previous studies comparing HRQOL of ALL survivors with
population norms found similar results. Zeltzer and colleagues
(2009) compared ALL survivors with US norms and siblings [22].
Table 1. Characteristics of non-participants and participants.
Non-participants Participants
All (n =164) All (n = 457) Relapse (n=61) Non-Relapse (n =396)
n % n % pa n % n % pb
Gender Male 107 65.2 229 50.1 36 59.0 193 48.7
Female 57 34.8 228 49.9 0.001 25 41.0 203 51.3 0.135
Current age 16–24.9 y 75 45.7 236 51.6 26 42.6 210 53.0
25–29.9 y 31 18.9 110 24.1 12 19.7 98 24.7
30–34.9 y 28 17.1 62 13.6 12 19.7 50 12.6
$35 y 25 15.2 49 10.7 0.057 11 18.0 38 9.6 0.015
Having a partner No n/a 234 51.2 32 52.5 202 51.0
Yes n/a 209 45.7 n/a 27 44.3 182 46.0 0.815
Education Compulsory schooling n/a 114 24.9 13 21.3 101 25.5
Vocational training n/a 179 39.2 29 47.5 150 37.9
Upper secondary educationc n/a 88 19.3 11 18.0 77 19.4
University education n/a 58 12.7 n/a 7 11.5 51 12.9 0.966
Age at diagnosis 0–4.9 y 72 43.9 227 49.7 29 47.5 198 50.0
5–9.9 y 56 34.1 136 29.8 20 32.8 116 29.3
$10 y 36 22.0 94 20.6 0.317 12 19.7 82 20.7 0.895
Time since diagnosis 5–14.9 y 44 26.8 125 27.4 8 13.1 117 29.5
15–24.9 y 52 31.7 239 52.3 32 52.5 207 52.3
$25 38 23.2 93 20.4 0.717 21 34.4 72 18.2 0.001
Chemo2/Radiotherapy Chemotherapyd 104 63.4 312 68.3 8 13.1 304 76.8
Radiotherapye 60 36.6 145 31.7 0.257 53 86.9 92 23.2 ,0.001
No 157 95.7 409 89.5 41 67.2 368 92.9
Yes 7 4.3 48 10.5 0.016 20 32.8 28 7.1 ,0.001
Duration of therapy #2 y 101 61.6 305 66.7 18 29.5 287 72.5
.3 y 42 25.6 119 26.0 0.765 42 68.9 77 19.4 ,0.001
Self-reported late effects No n/a 334 73.1 26 42.6 308 77.8
Yes n/a 119 26.0 n/a 35 57.4 84 21.2 ,0.001
Relapse status No 133 81.1 396 86.7 0 0 396 100
Yes 31 18.9 61 13.3 0.086 61 100 0 0 n/a
Abbreviation: n/a, not applicable.
aall non-participants vs. all participants; p-values calculated from chi-square statistics.
brelapsed vs. non-relapsed participants; p-values calculated from chi-square statistics.
cincludes high school, teachers training colleges, technical colleges and upper vocational education.
dwithout radiotherapy, may have surgery.
ewith or without chemotherapy or surgery.
doi:10.1371/journal.pone.0038015.t001
Quality of Life after Relapsed Childhood Leukemia
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e38015
Table 2. SF-36 scales, in all survivors and comparing those with and without relapse.
Unadjusted Adjusted, full modela
All
(n = 457)
Non-relapse
(n =396)
Relapse
(n =61) p
All
(n = 457)
Non-relapse
(n=396)
Relapse
(n =61) pb
Physical functioning Mean 52.0 52.1 50.8 0.126 52.0 51.8 53.4 0.219
95CI [51.2–52.7] [51.4–52.9] [48.8–52.8] [51.3–52.8] [51.0–52.6] [51.1–55.7]
Role physical Mean 51.0 51.1 49.8 0.132 51.0 51.0 51.2 0.817
95CI [50.3–51.6] [50.5–51.8] [47.9–51.7] [50.4–51.6] [50.3–51.7] [49.2–53.3]
Bodily pain Mean 57.1 57.1 57.1 0.781 57.1 56.9 58.3 0.245
95CI [56.5–57.8] [56.4–57.9] [55.2–58.9] [56.4–57.8] [56.1–57.7] [56.1–60.5]
General health Mean 55.3 55.8 51.6 0.005 55.4 55.8 53.0 0.135
95CI [54.2–56.3] [54.7–57.0] [48.6–54.7] [54.3–56.5] [54.6–57.0] [49.6–56.4]
Vitality Mean 57.0 57.4 54.3 0.087 57.0 57.1 56.1 0.606
95CI [55.8–58.1] [56.1–58.6] [50.7–57.8] [55.8–58.1] [55.8–58.4] [52.3–59.8]
Social functioning Mean 50.9 51.1 49.3 0.113 50.9 51.0 50.6 0.799
95CI [50.0–51.8] [50.2–52.1] [46.2–52.4] [50.0–51.9] [50.0–52.0] [47.6–53.5]
Role emotional Mean 48.8 49.1 47.4 0.230 48.8 48.8 48.7 0.931
95CI [48.0–49.6] [48.2–49.9] [44.7–50.1] [47.9–49.6] [47.9–49.7] [46.0–51.3]
Mental health Mean 54.0 54.2 52.8 0.488 54.0 54.0 53.9 0.989
95CI [53.0–55.0] [53.1–55.2] [49.9–55.7] [52.9–55.0] [52.8–55.1] [50.7–57.2]
Abbreviation: 95CI, 95% confidence interval.
aadjusted for gender, current age, time since diagnosis, having a partner, education, chemo2/radiotherapy, bone marrow transplantation, duration of therapy, and self-
reported late effects.
bp-values calculated from likelihood-ratio tests.
doi:10.1371/journal.pone.0038015.t002
Figure 2. Short Form-36 scales, in all survivors and by relapse status, adjusted results. Full model, adjusted for gender, current age, time
since diagnosis, having a partner, education, chemo2/radiotherapy, bone marrow transplantation, duration of therapy, and self-reported late effects;
German population norm used. SF-36: Short Form-36.
doi:10.1371/journal.pone.0038015.g002
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Table 3. Distribution of the answers to items of the general health scale, overall and by relapse status.
All
(n = 457) Relapse (n =61) Non-relapse (n =396) p
N % n % 95CI n % 95CI
I seem to get sick a little easier than other people definitively true 23 5.1 4 6.7 0.2 – 13.2 19 4.8 2.7 – 7.0 0.051
mostly true 47 10.4 7 11.7 3.3 – 20.0 40 10.2 7.2 – 13.2
don’t know 49 10.8 10 16.7 7.0 – 26.4 39 9.9 7.0 – 12.9
mostly false 99 21.9 15 25.0 13.7 – 36.3 84 21.4 17.3 – 25.4
definitively false 235 51.9 24 40.0 27.2 – 52.8 211 53.7 48.7 – 58.6
I am as healthy as anybody I know definitively true 249 55.1 22 36.7 24.1 – 49.2 227 57.9 53.0 – 62.8 0.006
mostly true 119 26.3 23 38.3 25.7 – 51.0 96 24.5 20.2 – 28.8
don’t know 34 7.5 7 11.7 3.3 – 20.0 27 6.9 4.4 – 9.4
mostly false 34 7.5 7 11.7 3.3 – 20.0 27 6.9 4.4 – 9.4
definitively false 16 3.5 1 1.7 21.7 – 5.0 15 3.8 1.9 – 5.7
I expect my health to get worse definitively true 3 0.7 1 1.7 21.7 – 5.1 2 0.5 20.2 – 1.2 0.045
mostly true 16 3.6 4 6.8 0.2 – 13.4 12 3.1 1.4 – 4.8
don’t know 63 14.0 12 20.3 9.8 – 30.9 51 13.1 9.7 – 16.4
mostly false 65 14.5 8 13.6 4.6 – 22.6 57 14.6 11.1 – 18.1
definitively false 302 67.3 34 57.6 44.6 – 70.6 268 68.7 64.1 – 73.3
My health is excellent definitively true 239 53.0 23 39.0 26.2 – 51.8 216 55.1 50.2 – 60.0 0.004
mostly true 151 33.5 20 33.9 21.5 – 46.3 131 33.4 28.7 – 38.1
don’t know 26 5.8 7 11.9 3.4 – 20.4 19 4.8 2.7 – 7.0
mostly false 21 4.7 7 11.9 3.4 – 20.4 14 3.6 1.7 – 5.4
definitively false 14 3.1 2 3.4 21.4 – 8.1 12 3.1 1.3 – 4.8
Abbreviation: 95CI, 95% confidence interval.
doi:10.1371/journal.pone.0038015.t003
Table 4. Comparison of papers on the association of childhood cancer relapse with HRQOL.
Cohort Sample Size
Type of
Cancer
Measurement
Tool Multivariable result
Independent variables in
multivariable regressions
Present paper Population based
Swiss Childhood
Cancer Survivor
Study
396 N-R, 61 R ALL SF-36 Survivors of relapsed and
non-relapsed ALL had similar
HRQOL, except in general
health. In regression analysis,
this difference was
explained by late effects.
Gender, age, time since diagnosis,
having a partner, education,
chemo2/radiotherapy, bone
marrow transplantation, duration of
therapy, self- reported late effects
and relapse
Stam and colleagues
(2006) [14]
Attendants of Dutch
long-term follow-up
clinic
310 N-R, 43 R mixed SF-36 Relapse did not contribute
to HRQOL.
Gender, age, diagnosis, treatment,
age at first diagnosis, duration of
treatment, and ‘‘relapse or second
malignancy’’
Zebrack and Chesler
(2002) [15]
Former patients of a
‘‘mid-western children’s
hospital’’
160 N-R, 15 R mixed Quality of
Life-Cancer
Survivors
Relapse did not contribute
to HRQOL.
Gender, age, parent income, living
arrangement, diagnosis, medical
condition, age at diagnosis, after-
effects reported and relapse
Maunsell and
colleagues (2006) [16]
Canadian Childhood
Cancer Surveillance and
Control
Program
1178 N-R, 156 R mixed SF-36, self-
esteem and
optimism
scales,
satisfaction
with life scale
More than one treatment
series (as a proxy for relapse)
was independently associated
with poorer HRQOL in
the physical dimensions.
‘‘CNS or bone cancer’’, two organs
with dysfunction, ‘‘all three
treatment modalities’’ (surgery,
chemo-, and radiotherapy), cranial
radiation, more than one treatment
series
Harila and colleagues
(2010) [17]
Hospital-based study
in Oulu/Finland
63 N-R, 11 R ALL SF-36 2 2
Abbreviations: N-R, Survivors of non-relapsed childhood cancer; R, Survivors of relapsed childhood cancer; ALL, acute lymphoblastic leukemia; SF-36, Short Form-36;
HRQOL, health-related quality of life; CNS, central nervous system.
doi:10.1371/journal.pone.0038015.t004
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Survivors had lower SF-36 means for physical function, role
physical, role emotional, and vitality than the norm population,
but they were still well within one standard deviation of the norm.
In a study by Reulen and colleagues (2007) used the SF-36
physical and mental summary measures to compare 2558
leukemia survivors with British norms and found no difference
[20]. Neither was a difference found between ALL survivors and
their control relatives when Short Form-12 (SF-12) was used [21].
In Zebrack and Chesler’s study (2002), relapse did not
contribute to HRQOL, even when late effects were adjusted for
[15]. The latter supports our findings, but a Canadian study found
that more than one treatment series (as a proxy for relapse) was
independently associated with poorer quality of life in the physical
dimensions, even when major late effects were adjusted for [16]. In
contrast, a Finnish study found higher scores for vitality and
mental health in relapsed ALL survivors compared to healthy
controls [17]. However, the analysis was not adjusted.
Possible Explanations and Implications
Several earlier studies attempted to explain the rather surprising
result that childhood cancer survivors often report similar or better
HRQOL than general populations. Survivors’ subjective percep-
tion of HRQOL may be affected by a desire to be ‘‘as normal as
possible,’’ causing a response shift (a change in the meaning of
one’s self-evaluation of quality of life) [36]. Caught in the
‘‘paradox of satisfaction [38],’’ childhood cancer survivors also
tend to deny difficulties on QOL measures [37] and to report high
QOL even under difficult living conditions. But surviving
childhood cancer may also result in post-traumatic growth or
thriving [39,40], suggesting that survivors may indeed experience
high QOL despite problems.
Relapsed and non-relapsed ALL survivors reported on similar
HRQOL, except on one SF-36 scale. In relapsed patients, general
health was significantly poorer, very likely as a consequence of late
effects associated with relapse. As it was described in earlier
studies, those late effects can become severe; therefore, our results
have implications for follow-up care: We encourage specialists who
conduct follow-up to screen for poor general health in survivors
after a relapse and, when appropriate, specifically seek and treat
underlying late effects.
Open Questions and Future Research
The small effect we found in the present study requires in-depth
investigation in larger groups of patients. Treatment intensity,
adjuvant radiotherapy and stem cell transplantation with myeloa-
blative regimens may induce a series of somatic and mental late
chronic conditions after a relapse almost unknown after first-line
treatments for pediatric ALL. We should attempt to better
describe and quantify late effects by promoting regular long-term
follow-up visits, where survivors can be examined and interviewed.
Further preventing and minimizing late effects will help to
improve quality of life in survivors of ALL, particularly those
who had experienced a relapse.
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